MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$29,105K
Net Income
-$11,663K
Net Profit Margin
-40.07%
EPS
-$0.12
Unit: Thousand (K) dollars
Revenue Breakdown
Gyre Pharmaceuticals
Gyre
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
29,105
22,519
30,586*
30,564
Cost of revenues
2,209
1,227
1,248*
1,628
Selling and marketing
13,754
14,136
16,618*
15,328
Research and development
-
6,738
6,609*
2,363
Research and development-Nonrelated Party
14,300
-
-
-
Research and development-Related Party
4,836
-
-
-
General and administrative
7,867
7,220
7,847*
4,319
Loss on disposal of assets, net
-
-
-1*
-1
Transaction costs
502
2,553
-
-
Total operating expenses
43,468
31,874
32,322*
23,639
(gain) income from operations
-14,363
-9,355
-1,736*
6,925
Interest income
740
-
437*
-
Other expense, net
-943
29
-3,686*
727
Change in fair value of warrant liability
-132
-89
-2,776*
23
(gain) income before income taxes
-14,434
-9,237
-2,209*
7,629
Benefit (provision) for income taxes
-164
621
-523*
1,693
Net (gain) income from consolidated operations
-14,270
-9,858
-1,686*
5,936
Accretion of cullgen redeemable convertible preferred stock
1,058
-
-
-
Less allocation of undistributed gain to noncontrolling interest
-3,665
-1,167
-337*
2,326
Net (gain) income attributable to common stockholders
-11,663
-8,691
-1,349
3,610
Basic EPS
-0.12
-0.1
-0.015
0.04
Diluted EPS
-0.12
-0.1
-0.013
0.03
Basic Average Shares
100,637,599
91,317,142
88,064,482
90,850,040
Diluted Average Shares
100,637,599
91,344,584
102,866,858
103,971,546
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net (gain) income
attributable to common...
-$11,663K
Less allocation of
undistributed gain to...
-$3,665K
(-423.19%↓ Y/Y)
Net (gain) income
from consolidated...
-$14,270K
(-1005.46%↓ Y/Y)
Benefit (provision) for
income taxes
-$164K
Accretion of cullgen
redeemable convertible...
$1,058K
(gain) income before
income taxes
-$14,434K
Interest income
$740K
Change in fair value of
warrant liability
-$132K
Gyre
Pharmaceuticals
$29,097K
Gyre
$8K
(gain) income from
operations
-$14,363K
Other expense, net
-$943K
Revenues
$29,105K
(8.72%↑ Y/Y)
Total operating
expenses
$43,468K
Research and
development-Nonrelated Party
$14,300K
Selling and marketing
$13,754K
General and
administrative
$7,867K
Research and
development-Related Party
$4,836K
Cost of revenues
$2,209K
(91.92%↑ Y/Y)
Transaction costs
$502K
Buy us a coffee
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)